RESUMEN
ABSTRACT Objective: Initial diagnosis of medullary thyroid carcinoma (MTC) is frequently associated with advanced stages and a poor prognosis. Thus, the need for earlier diagnoses and detection in relatives at risk for the disease has led to increased use of RET genetic screening. Subjects and methods: We performed RET screening in 247 subjects who were referred to the Brazilian Research Consortium for Multiple Endocrine Neoplasia (BRASMEN) Center in the State of Ceará. Direct genetic sequencing was used to analyze exons 8, 10, 11, and 13-16 in MTC index cases and specific exons in at risk relatives. Afterward, clinical follow-up was offered to all the patients with MTC and their affected relatives. Results: RET screening was performed in 60 MTC index patients and 187 at-risk family members. At the initial clinical assessment of the index patients, 54 (90%) were diagnosed with apparently sporadic disease and 6 (10%) diagnosed with hereditary disease. After RET screening, we found that 31 (52%) index patients had sporadic disease, and 29 (48%) had hereditary disease. Regarding at-risk relatives, 73/187 were mutation carriers. Mutations in RET codon 804 and the rare p.M918V mutation were the most prevalent. Conclusions: Performing RET screening in Ceará allowed us to identify a different mutation profile in this region compared with other areas. RET screening also enabled the diagnosis of a significant number of hereditary MTC patients who were initially classified as sporadic disease patients and benefited their relatives, who were unaware of the risks and the consequences of bearing a RET mutation.
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/genética , Mutación de Línea Germinal/genética , Carcinoma Neuroendocrino/diagnóstico , Carcinoma Neuroendocrino/genética , Proteínas Proto-Oncogénicas c-ret/genética , Tamización de Portadores Genéticos/métodos , Factores de Tiempo , Brasil , Neoplasias de la Tiroides/patología , Inmunohistoquímica , Transfección/métodos , Reordenamiento Génico/genética , Reproducibilidad de los Resultados , Factores de Riesgo , Factores de Edad , Carcinoma Neuroendocrino/patología , Medición de Riesgo , Detección Precoz del Cáncer , Estudios de Asociación GenéticaRESUMEN
ABSTRACT Purpose: The present study evaluates chondroitin sulfate (CS) and heparan sulfate (HS) in the urine and hyaluronic acid (HA) in the plasma of patients with prostate cancer before and after treatment compared to a control group. Materials and Methods: Plasma samples were used for HA dosage and urine for quantification of CS and HS from forty-four cancer patients and fourteen controls. Clinical, laboratory and radiological information were correlated with glycosaminoglycan quantification by statistical analysis. Results: Serum HA was significantly increased in cancer patients (39.68 ± 30.00 ng/ mL) compared to control group (15.04 ± 7.11 ng/mL; p=0.004) and was further increased in high-risk prostate cancer patients when compared to lower risk patients (p = 0.0214). Also, surgically treated individuals had a significant decrease in seric levels of heparan sulfate after surgical treatment, 31.05 ± 21.01 μg/mL (before surgery) and 23.14 ± 11.1 μg/mL (after surgery; p=0.029). There was no difference in the urinary CS and HS between prostate cancer patients and control group. Urinary CS in cancer patients was 27.32 ± 25.99 μg/mg creatinine while in the men unaffected by cancer it was 31.37 ± 28.37 μg/mg creatinine (p=0.4768). Urinary HS was 39.58 ± 32.81 μg/ mg creatinine and 35.29 ± 28.11 μg/mg creatinine, respectively, in cancer patients and control group (p=0.6252). Conclusions: Serum HA may be a useful biomarker for the diagnosis and prognosis of prostate cancer. However, urinary CS and HS did not altered in the present evaluation. Further studies are necessary to confirm these preliminary findings.
Asunto(s)
Humanos , Masculino , Anciano , Neoplasias de la Próstata/orina , Neoplasias de la Próstata/sangre , Sulfatos de Condroitina/orina , Heparitina Sulfato/orina , Ácido Hialurónico/sangre , Biomarcadores de Tumor/orina , Biomarcadores de Tumor/sangre , Estudios de Casos y Controles , Estudios Prospectivos , Persona de Mediana EdadRESUMEN
ABSTRACT Thyroglobulin (Tg) is the major glycoprotein produced by the thyroid gland, where it serves as a template for thyroid hormone synthesis and as an intraglandular store of iodine. Measurement of Tg levels in serum is of great practical importance in the follow-up of differentiated thyroid carcinoma (DTC), a setting in which elevated levels after total thyroidectomy are indicative of residual or recurrent disease. The most recent methods for serum Tg measurement are monoclonal antibody-based and are highly sensitive. However, major challenges remain regarding the interpretation of the results obtained with these immunometric methods, particularly in patients with endogenous antithyroglobulin antibodies or in the presence of heterophile antibodies, which may produce falsely low or high Tg values, respectively. The increased prevalence of antithyroglobulin antibodies in patients with DTC, as compared with the general population, raises the very pertinent possibility that tumor Tg may be more immunogenic. This inference makes sense, as the tumor microenvironment (tumor cells plus normal host cells) is characterized by several changes that could induce posttranslational modification of many proteins, including Tg. Attempts to understand the structure of Tg have been made for several decades, but findings have generally been incomplete due to technical hindrances to analysis of such a large protein (660 kDa). This review article will explore the complex structure of Tg and the potential role of its marked heterogeneity in our understanding of normal thyroid biology and neoplastic processes.
Asunto(s)
Humanos , Procesamiento Proteico-Postraduccional , Enfermedades de la Tiroides , Tiroglobulina/metabolismo , Biomarcadores de Tumor/sangre , Glicosilación , Halogenación , Fosforilación , Tiroglobulina/química , Enfermedades de la Tiroides/sangre , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/etiología , Enfermedades de la Tiroides/prevención & control , Hormonas Tiroideas/biosíntesisRESUMEN
Objective Consuming a low-iodine diet (LID) is a widely accepted practice before administering radioiodine (131I) to evaluate and to treat thyroid disease. Although this procedure is well established for the management of patients with differentiated thyroid cancer, its use in patients with benign disease is unclear. So, we aimed to evaluate the influence of a LID on the outcome in patients with Graves’ disease (GD) treated with131I. Subjects and methods We evaluated 67 patients with GD who were divided into 2 groups: one group (n = 31) consumed a LID for 1-2 weeks, and the second group (n = 36) was instructed to maintain a regular diet (RD). Results The LID group experienced a 23% decrease in urinary iodine after 1 week on the diet and a significant 42% decrease after 2 weeks on the diet. The majority (53%) of the patients in the LID group had urinary iodine levels that were consistent with deficient iodine intake. However, there was no difference in the rate of hyperthyroidism’s cure between the LID and the RD groups 6 months after 131I therapy. Furthermore, the therapeutic efficacy did not differ in patients with varying degrees of sufficient iodine intake (corresponding urinary iodine levels: < 10 μg/dL is deficient; 10-29.9 μg/dL is sufficient; and > 30 μg/dL is excessive). Conclusion In the present study, we demonstrated that although a LID decreased urinary iodine levels, those levels corresponding with sufficient or a mild excess in iodine intake did not compromise the therapeutic efficacy of131I for the treatment of GD.
Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Enfermedad de Graves/dietoterapia , Enfermedad de Graves/tratamiento farmacológico , Radioisótopos de Yodo/uso terapéutico , Yodo/administración & dosificación , Oligoelementos/farmacología , Terapia Combinada , Estudios de Seguimiento , Alimentos Formulados , Yodo/orina , Estado Nutricional , Resultado del TratamientoRESUMEN
Tick species parasitizing yellow armadillo, Euphractus sexcinctus, were recorded from October 2006 to October 2007 in Pantanal. A total of 89 ticks were collected from 23 yellow armadillos. Most ticks (n = 50) were identified as Amblyomma cajennense (Fabricius) (32 males and 18 females). The only other species found was Amblyomma parvum (Aragão) (three females and two males). The remaining ticks were immatures of Amblyomma (29 nymphs and five larvae). The prevalence of A. cajennense was 55 percent, the mean intensity was 2.7 ± 0.5 (SE) (n = 17) and the mean abundance was 1.5 ± 0.4 (n = 31).
Asunto(s)
Animales , Femenino , Masculino , Armadillos/parasitología , Ixodidae/fisiología , Brasil , HumedalesRESUMEN
PURPOSE: We reproduced a non-bacterial experimental model to assess bladder inflammation and urinary glycosaminoglycans (GAG) excretion and examined the effect of dimethyl sulfoxide (DMSO). MATERIALS AND METHODS: Female rats were instilled with either protamine sulfate (PS groups) or sterile saline (control groups). At different days after the procedure, 24 h urine and bladder samples were obtained. Urinary levels of hyaluronic acid (HA) and sulfated glycosaminoglycans (S-GAG) were determined. Also to evaluate the effect of DMSO animals were instilled with either 50 percent DMSO or saline 6 hours after PS instillation. To evaluate the effect of DMSO in healthy bladders, rats were instilled with 50 percent DMSO and controls with saline. RESULTS: In the PS groups, bladder inflammation was observed, with polymorphonuclear cells during the first days and lymphomononuclear in the last days. HA and S-GAG had 2 peaks of urinary excretion, at the 1st and 7th day after PS injection. DMSO significantly reduced bladder inflammation. In contrast, in healthy bladders, DMSO produced mild inflammation and an increase in urinary HA levels after 1 and 7 days and an increase of S-GAG level in 7 days. Animals instilled with PS and treated with DMSO had significantly reduced levels of urinary HA only at the 1st day. Urinary S-GAG/Cr levels were similar in all groups. CONCLUSIONS: Increased urinary levels of GAG were associated with bladder inflammation in a PS-induced cystitis model. DMSO significantly reduced the inflammatory process after urothelial injury. Conversely, this drug provoked mild inflammation in normal mucosa. DMSO treatment was shown to influence urinary HA excretion.
Asunto(s)
Animales , Femenino , Ratas , Cistitis Intersticial/orina , Glicosaminoglicanos/orina , Ácido Hialurónico/orina , Protaminas/uso terapéutico , Biomarcadores/orina , Cistitis Intersticial/tratamiento farmacológico , Modelos Animales de Enfermedad , Dimetilsulfóxido/farmacología , Ratas WistarRESUMEN
Amblyomma fuscum conhecida somente no Brasil, tem sido descrita como uma espécie rara de carrapato com relatos de sua ocorrência nas regiões sul e sudeste. Este é um novo registro desta espécie (9 fêmeas) parasitando lagarto (Tupinambis teguixin), no Município de Glorinha, Estado do Rio Grande do Sul. As fêmeas foram depositadas na coleção do Instituto de Pesquisas Veterinárias Desidério Finamor (7 espécimes) e na coleção de Acari do Instituto Butantan, Estado de São Paulo (2 espécimes). O achado confirma o estabelecimento de A. fuscum no Sul do Brasil.
Amblyomma fuscum known only from Brazil has been described as a rare tick species with few reports of its occurrence in South and Southeast region. This is a new records this tick species (9 females) parasitizing lizard (Tupinambis teguixin) at the Municipality of Glorinha, State of Rio Grande do Sul. The females were deposited in the tick collection of Veterinary Research Institute Desiderio Finamor (7 specimens), Eldorado do Sul, RS and in the Acari collection from Instituto Butantan, São Paulo, State of São Paulo (2 specimens). The finding confirms establishment de A. fuscum in the South of Brazil.